Related Experiment Videos
[Growth in children with diabetes insipidus]
Boletin Medico Del Hospital Infantil De Mexico
|November 1, 1980
Summary
Treatment for diabetes insipidus in Mexico uses a hydrochlorothiazide preparation, limiting but not correcting impaired growth. Early intervention is crucial to prevent further growth deterioration.
Area of Science:
- Pediatric Endocrinology
- Nephrology
- Growth Disorders
Context:
- Commercial vasopressin preparations are unavailable in Mexico.
- Vasopressin is ineffective for nephrogenic diabetes insipidus.
- A local preparation (hydrochlorothiazide, aminopyrine, potassium chloride) is used for all diabetes insipidus types.
Purpose:
- To investigate the impact of a specific treatment regimen on statural growth in pediatric patients with diabetes insipidus.
- To evaluate growth patterns in patients with various etiologies of diabetes insipidus.
Summary:
- A study followed 44 pediatric patients with diabetes insipidus (idiopathic, histiocytosis, nephrogenic, etc.) treated with hydrochlorothiazide combination therapy for 2-12 years.
- While the treatment limited stature impairment, it did not result in catch-up growth.
- Some patients showed growth below the third percentile, while others progressively departed from their initial centile, sometimes indicating additional pathologies like growth hormone deficiency.
Impact:
- The current therapy effectively mitigates growth impairment in diabetes insipidus but does not reverse it.
- Early initiation of treatment is recommended to minimize long-term effects on stature.
- Deterioration in growth trajectory warrants investigation for co-existing conditions beyond diabetes insipidus.